Diabetic Kidney Disease: Evidence-Based Treatments and Outcomes

Evidence related to diabetic kidney disease

Evidence related to diabetic kidney disease, albuminuria, kidney function, nephropathy progression, end-stage renal disease, and kidney-protective diabetes treatments.

Build your Evidence Workspace

Save evidence about the topics you care about.

Studies

Evidence Pairs

Moderate Research Support

Relationship Confidence: 62/100

Evidence Intelligence™

Evidence Summary

A structured summary of where the evidence is strongest, mixed, or still emerging.

Executive Summary

Diabetic Kidney Disease evidence appears to center on Dapagliflozin.

Among 9 indexed studies and 7 interventions, the strongest signals are summarized from the available evidence. Dapagliflozin appears to be one of the clearer current evidence signals.

Evidence is consistently positive across multiple studies.
Some evidence is positive, but results are not consistent across all studies.
Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Freshness

Latest indexed evidence: June 2026

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Dapagliflozin appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies

Evidence basis: 4 evidence pairs - 3 studies

Why this appears here

Moderate evidenceConsistent resultsPositive effect signalMultiple studies

Dapagliflozin

3 studies

EvidenceScore™

63/100

ConsistencyScore™

71/100

Evidence Snapshot

Studies

Interventions

Outcomes

Strong evidence signals

Mixed evidence areas

Evidence freshness

Jun 2026

Latest indexed

Key Findings

Key patterns and insights identified across the research landscape

Moderate positive signal

Dapagliflozin may improve Urinary albumin-to-creatinine ratio

Dapagliflozin → Urinary albumin-to-creatinine ratio

Across 2 studies, Dapagliflozin shows a consistent moderate positive signal for Urinary albumin-to-creatinine ratio.

2 studies

EvidenceScore™: 63.07692307692308/100

View supporting studies

Strong positive signal

Dapagliflozin shows strong evidence for improving Estimated glomerular filtration rate

Dapagliflozin → Estimated glomerular filtration rate

Across 1 study, Dapagliflozin shows a strong positive signal for Estimated glomerular filtration rate.

1 studies

EvidenceScore™: 59/100

View supporting studies

Strong positive signal

Dapagliflozin shows strong evidence for improving Renal and urinary disorders incidence

Dapagliflozin → Renal and urinary disorders incidence

Across 1 study, Dapagliflozin shows a strong positive signal for Renal and urinary disorders incidence.

1 studies

EvidenceScore™: 59/100

View supporting studies

Neutral signal

Empagliflozin shows limited or neutral effect on Urinary albumin-to-creatinine ratio

Empagliflozin → Urinary albumin-to-creatinine ratio

Across 1 study, Empagliflozin shows a neutral signal for Urinary albumin-to-creatinine ratio.

1 studies

EvidenceScore™: 59/100

View supporting studies

Evidence signal

Empagliflozin shows evidence for Urinary L-FABP

Empagliflozin → Urinary L-FABP

Across 1 study, Empagliflozin shows a evidence signal for Urinary L-FABP.

1 studies

EvidenceScore™: 59/100

View supporting studies

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Dapagliflozin is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

Dapagliflozin

Empagliflozin

Dapagliflozin

3 studies

EvidenceScore™

63/100

ConsistencyScore™

71/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results PresentNegative Results Present

Evidence basis: 12 evidence pairs - 7 studies

View supporting studies

Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Dapagliflozin may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Dapagliflozin

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

Dapagliflozin

3 studies

EvidenceScore™

63/100

ConsistencyScore™

71/100

Why this appears here

Positive effect signalLimited study volumeFew randomized trialsEmerging Or Limited Strength

Evidence basis: 10 evidence pairs - 6 studies

View supporting studies

Explore the Evidence

The sections below provide the complete evidence questions, supporting relationships, and underlying studies behind the summary above.

Questions Answered by the Evidence

Does Dapagliflozin improve urinary albumin-to-creatinine ratio?

intervention effectiveness

Moderate Evidence

Dapagliflozin may improve Urinary albumin-to-creatinine ratio.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Dapagliflozin
EvidenceScore™ Moderate | EvidenceScore™ 63.1 | moderate positive | ConsistencyScore™ Consistent | 2 studies

Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.

Limitations

Only a small number of supporting studies are available.
Population details are unavailable.

Does SGLT2 inhibitors improve albuminuria?

intervention effectiveness

Emerging Evidence

SGLT2 inhibitors appears to improve Albuminuria.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
SGLT2 inhibitors
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

Does Empagliflozin improve urinary albumin-to-creatinine ratio?

intervention effectiveness

Emerging Evidence

Current evidence does not show a clear benefit of Empagliflozin for Urinary albumin-to-creatinine ratio.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Empagliflozin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

Does Finerenone (nonsteroidal mineralocorticoid receptor antagonist) improve albuminuria?

intervention effectiveness

Emerging Evidence

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Albuminuria.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

Does Dapagliflozin improve estimated glomerular filtration rate?

intervention effectiveness

Emerging Evidence

Dapagliflozin appears to improve Estimated glomerular filtration rate.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Dapagliflozin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

Does Finerenone (nonsteroidal mineralocorticoid receptor antagonist) improve composite renal outcomes (kidney failure, sustained egfr decline ≥57%, renal death)?

intervention effectiveness

Emerging Evidence

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Composite renal outcomes (kidney failure, sustained eGFR decline ≥57%, renal death).

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

Does SGLT2 inhibitors reduce renal and urinary disorders incidence?

intervention effectiveness

Emerging Evidence

Current evidence does not show a clear benefit of SGLT2 inhibitors for Renal and urinary disorders incidence.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
SGLT2 inhibitors
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

Does Pentoxifylline improve albuminuria?

intervention effectiveness

Emerging Evidence

Pentoxifylline appears to improve Albuminuria.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Pentoxifylline
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

Evidence summary for AI and search

Among 9 indexed studies and 7 interventions, the strongest signals are summarized from the available evidence. Dapagliflozin appears to be one of the clearer current evidence signals.